DNAVEC Corporation – Gene Medicines, Cell Therapy and Regenerative Medicines
- Company Name: DNAVEC Corporation
- City/Town/Village: Tsukuba
- Street: 6 Okubo
- Country: Japan
- Zip/Postal Code: 300-2611
- Listed: 04/04/2013 1:11 am
- Expires: This ad has expired
DNAVEC Corporation (DNAVEC) is a workshop where scientists and engineers work together to realize their dreams of improving people’s health and conquering incurable diseases by exploiting front-edge bioscience and technologies to their full potential. DNAVEC is also a stage or base where the valuable efforts of our collaborators and supporters will come to big fruition. We believe that the promotion of creative collaborations with worldwide partners using our unique gene transfer technologies are the driving force of rapid and sure creation of valuable products and services.
DNAVEC wishes to contribute to the human society not only by meeting the medical needs of numerous afflicted people suffering from chronic, hereditary, or infectious diseases but also by applying its technologies to wider use in bio-business in general. DNAVEC will perform its management with the merits of continuity, expansibility and multiplicity of the business that maximally utilize the broad applicability of its vector technologies.
Core Technologies of DNAVEC
Sendai Virus Vector (SeV Vector): A Cytoplasmic RNA Vector
Sendai virus vector (SeV vector) is a vector based on the novel concept “Cytoplasmic RNA vector” that DNAVEC has successfully brought into practical use for the first time in the world. Its applications include a wide range of important bio-businesses such as gene therapy, gene vaccine, therapeutic antibody production, gene function analysis, and recombinant protein production. With this vector, DNAVEC is about to play an important role in medicine by bringing a new approach to the treatment of intractable diseases.
Simian Immunodeficiency Virus Vector (SIV vector)
A vector derived from Simian Immunodeficiency Virus (SIV). This vector is similar to Human Immunodeficiency Virus (HIV, AIDS virus)-based vectors in many aspects, which are now entering clinical trials in the US. Both SIV and HIV are members of lentivirus family, whose characteristics include capabilities to introduce genes efficiently into not only actively dividing cells but also terminally differentiated cells such as neurons, and to maintain gene expression for a long period of time.
DNAVEC’s Business Profile
DNAVEC utilizes its own vector platforms such as Sendai virus vector in its business development, resulting in merits that are not readily available to other bio-companies.
- Gene Therapy
- Gene Vaccine
- Therapeutic Antibody
- Protein Production
- Gene Function Analysis
Our Website: www.dnavec.co.jp
One Related article of “DNAVEC Corporation – Gene Medicines, Cell Therapy and Regenerative Medicines”
Leave a Reply
You must be logged in to post a comment.
Top Ads Today
- TSI Holdings Co., Ltd. - Offer more than 50 clothing brands for women (9 views)
- Kyoto Seisakusho Co., Ltd. - Manufacturing of packaging machines and processing machines (8 views)
- Nitride Semiconductors Co., Ltd. - World First successful development and mass production of UV LEDs (6 views)
- Japan's leading sporting goods manufacturer - ASICS Corporation (5 views)
- ABI Co., Ltd. - Freezer machine for keeping tissue cells alive (5 views)
- Daikin Industries, Ltd. - A leading Innovator of High-quality Air Conditioning Solutions (5 views)
- NSK Ltd. - NSK Produced the First Ball Bearings Made in Japan (5 views)
- Shimamura Co., Ltd. - 2nd largest clothing company in Japan and ranked 10th in the world in 2017 (5 views)
- Adastria Co., Ltd. - Japan's major clothing company with 26 brands (4 views)
- SHINKO IND. LTD. - Our Cargo Oil Pumps Occupies 85% of The Global Market (4 views)
The clinical trial of the new AIDS vaccine candidate by the Japanese technique starts in Africa
NEW YORK, NY; April 1 2013. The International AIDS Vaccine Initiative (IAVI) and DNAVEC announce the start of a multi-center Phase I clinical trial to evaluate the safety and tolerability of a novel preventive HIV vaccine candidate, SeV-G. Researchers also seek to obtain a preliminary assessment of the immune responses elicited by a prime-boost regimen of SeV-G and a vaccine candidate based on adenovirus serotype 35. This clinical trial is the first ever to test SeV-G.